Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204
Silexion Therapeutics Corp. recently announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the company’s management will be presenting at the upcoming Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27t-29, 2025, at The Roosevelt New Orleans Hotel in New Orleans, LA.
The newly completed strategic plan builds upon Silexion’s recent promising preclinical data and is designed to maximize SIL-204’s potential across multiple delivery approaches to address the challenges of KRAS-driven cancers. The Company plans to report further details on the expanded plan alongside its presentation at the conference.
A company presentation will take place during the conference’s Innovation track on Friday, March 28th at 1:00pm. During this session, Silexion will present its strategic vision alongside recently reported preclinical findings from its SIL-204 program.
“We look forward to sharing our expanded development plan for SIL-204 at the upcoming NeauxCancer Conference,” said Ilan Hadar, Chairman and CEO of Silexion Therapeutics. “Recent advances in our preclinical program have informed a more comprehensive approach to targeting KRAS-driven cancers, particularly pancreatic cancer. Our presentation will outline how we plan to leverage these findings to advance SIL-204 toward clinical development.”
Silexion’s management team will be available for one-on-one meetings during the conference. Interested investors should contact Silexion’s investor relations representatives as listed below.
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company’s first-generation product, LODER™, has shown promising results in a Phase 2 clinical trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com
Total Page Views: 163
